523 related articles for article (PubMed ID: 36737746)
41. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Chen WM; Yeh YH; Kuo CT; See LC; Lip GYH
Cardiovasc Diabetol; 2022 Jun; 21(1):118. PubMed ID: 35765074
[TBL] [Abstract][Full Text] [Related]
42. Weight-lowering Effects of Glucagon-like Peptide-1 Receptor Agonists and Detection of Breast Cancer Among Obese Women with Diabetes.
Santella C; Yin H; Hicks BM; Yu OHY; Bouganim N; Azoulay L
Epidemiology; 2020 Jul; 31(4):559-566. PubMed ID: 32282437
[TBL] [Abstract][Full Text] [Related]
43. Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - A systematic review and meta-analysis.
Yoshida Y; Joshi P; Barri S; Wang J; Corder AL; O'Connell SS; Fonseca VA
J Diabetes Complications; 2022 Aug; 36(8):108255. PubMed ID: 35817678
[TBL] [Abstract][Full Text] [Related]
44. The comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A Scandinavian cohort study.
Ueda P; Wintzell V; Dahlqwist E; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Melbye M; Hviid A; Svanström H; Pasternak B
Diabetes Obes Metab; 2022 Mar; 24(3):473-485. PubMed ID: 34738703
[TBL] [Abstract][Full Text] [Related]
45. The causal effect of hypertension, intraocular pressure, and diabetic retinopathy: a Mendelian randomization study.
Wang XF; Zhang XW; Liu YJ; Zheng XY; Su MR; Sun XH; Jiang F; Liu ZN
Front Endocrinol (Lausanne); 2024; 15():1304512. PubMed ID: 38379860
[TBL] [Abstract][Full Text] [Related]
46. Integrative analysis of Mendelian randomization and gene expression profiles reveals a null causal relationship between adiponectin and diabetic retinopathy.
Zhang A; Wu H; Wang C; Tian S
Adipocyte; 2023 Dec; 12(1):2234522. PubMed ID: 37459460
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.
De Block CEM; Dirinck E; Verhaegen A; Van Gaal LF
Diabetes Obes Metab; 2022 May; 24(5):788-805. PubMed ID: 34984793
[TBL] [Abstract][Full Text] [Related]
48. Decreased expression of Glucagon-like peptide-1 receptor and Sodium-glucose co-transporter 2 in patients with proliferative diabetic retinopathy.
Chen H; Zhang X; Liao N; Ji Y; Mi L; Gan Y; Su Y; Wen F
Front Endocrinol (Lausanne); 2022; 13():1020252. PubMed ID: 36465606
[TBL] [Abstract][Full Text] [Related]
49. Association between glucagon-like peptide-1 receptor agonists and biliary-related diseases in patients with type 2 diabetes: A nationwide cohort study.
Dong YH; Wu JH; Chang CH; Lin JW; Wu LC; Toh S
Pharmacotherapy; 2022 Jun; 42(6):483-494. PubMed ID: 35508702
[TBL] [Abstract][Full Text] [Related]
50. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.
Østergaard L; Frandsen CS; Madsbad S
Expert Rev Clin Pharmacol; 2016; 9(2):241-65. PubMed ID: 26573176
[TBL] [Abstract][Full Text] [Related]
51. Incretin-Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes.
Faillie JL; Yin H; Yu OHY; Herrero A; Altwegg R; Renoux C; Azoulay L
Clin Pharmacol Ther; 2022 Jan; 111(1):272-282. PubMed ID: 34587280
[TBL] [Abstract][Full Text] [Related]
52. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
Dawwas GK; Smith SM; Park H
Cardiovasc Diabetol; 2018 Jul; 17(1):102. PubMed ID: 30016946
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis.
Huthmacher JA; Meier JJ; Nauck MA
Diabetes Care; 2020 Sep; 43(9):2303-2312. PubMed ID: 32910778
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis.
Gargiulo P; Savarese G; D'Amore C; De Martino F; Lund LH; Marsico F; Dellegrottaglie S; Marciano C; Trimarco B; Perrone-Filardi P
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1081-1088. PubMed ID: 29113708
[TBL] [Abstract][Full Text] [Related]
55. Systemic inflammatory regulators and proliferative diabetic retinopathy: A bidirectional Mendelian randomization study.
Shi Q; Wang Q; Wang Z; Lu J; Wang R
Front Immunol; 2023; 14():1088778. PubMed ID: 36845092
[TBL] [Abstract][Full Text] [Related]
56. Pharmacogenetics of Glucagon-like Peptide-1 Agonists for the Treatment of Type 2 Diabetes Mellitus.
Karras SN; Rapti E; Koufakis T; Kyriazou A; Goulis DG; Kotsa K
Curr Clin Pharmacol; 2017; 12(4):202-209. PubMed ID: 29473524
[TBL] [Abstract][Full Text] [Related]
57. Association of glucagon-like peptide-1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system.
Zimmerman RS; Hobbs TM; Wells BJ; Kong SX; Kattan MW; Bouchard J; Chagin KM; Yu C; Sakurada B; Milinovich A; Weng W; Bauman JM; Pantalone KM
Diabetes Obes Metab; 2017 Nov; 19(11):1555-1561. PubMed ID: 28407414
[TBL] [Abstract][Full Text] [Related]
58. Potential disease biomarkers for diabetic retinopathy identified through Mendelian randomization analysis.
Zou X; Ye S; Tan Y
Front Endocrinol (Lausanne); 2023; 14():1339374. PubMed ID: 38274229
[TBL] [Abstract][Full Text] [Related]
59. GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?
Simó R; Hernández C
Diabetes; 2017 Jun; 66(6):1453-1460. PubMed ID: 28533296
[TBL] [Abstract][Full Text] [Related]
60. Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy.
Dhanapalaratnam R; Issar T; Lee ATK; Poynten AM; Milner KL; Kwai NCG; Krishnan AV
Diabetologia; 2024 Mar; 67(3):561-566. PubMed ID: 38189936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
